Notice of Change to Application Types Allowed for RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)"
Notice Number:
NOT-NS-22-025

September 7, 2021

Release Date:

Related Announcements

RFA-NS-21-010 - HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this notice is to inform applicants of a change to the Application Types Allowed for Funding Opportunity Announcement (FOA) RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)". The application types have been expanded to include Resubmission applications. This change is effective as of the October 15, 2021 due date.

The following sections of RFA-NS-21-010 have been modified:

Currently Reads:

Section II. Award Information

Application Types Allowed

New

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA.

Section V. Application Review Information

1. Criteria

Additional Review Criteria

Resubmissions

Not Applicable.

Modified to Read (changes shown in bold italics):

Section II. Award Information

Application Types Allowed

New

Resubmission

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA.

Section V. Application Review Information

1. Criteria

Additional Review Criteria

For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Charles Cywin, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
Email: charles.cywin@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices